Base de dados : LILACS
Pesquisa : D27.505.696.477.067 [Categoria DeCS]
Referências encontradas : 344 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 35 ir para página                         

  1 / 344 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1039131
Autor: Animal Science DepartmentSabioni, Rafael Estevan; Zanuzzo, Fábio Sabbadin; Animal Science DepartmentCyrino, José Eurico Possebon.
Título: Immunomodulation of Juvenile Pacu, Piaractus mesopotamicus, by Different ß(1-3)(1-6)-D glucan Products
Fonte: Braz. arch. biol. technol;62:e19170811, 2019. tab, graf.
Idioma: en.
Projeto: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Resumo: Abstract Stress in intensive fish farming hamper immune function of fish and cause losses by disease outbreaks, a situation that can be minimized, but cannot be completely circumvented, by the use of immunomodulators. Addition of immunomodulators to aquafeeds has thus become a common practice. β-glucan (BG) is one of most studied and effective immunomodulators, aquaculture purposes included. Extracted from cell walls of bacteria, fungi and selected cereals, BG activity depends on the source and extraction methods. This study evaluated effects of two BG products (BG1 and BG2), extracted from Saccharomyces cerevisiae under varying extraction methods and with different immune activity, on the feeding of pacu Piaractus mesopotamicus juveniles. BG1 provided higher leukocytes respiratory activity when fed at 0.5% inclusion for 10 days and 0.1% inclusion for 15 days. Both products seems to cause negative effect on lysozyme concentration and monocytes profile when fed to pacu for 15 days at 0.5% inclusion. Although the results for BG2 did not differ from control (diet devoid of BG), the proximity with the BG1 behavior is a indicative that a commercial product with smaller BG concentration can be effective when more refined technology is used in extraction process.
Descritores: Adjuvantes Imunológicos
Aquicultura
-Muramidase
Aeromonas hydrophila
Leucócitos
Responsável: BR1.1 - BIREME


  2 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1055400
Autor: Baleta, Francis Nuestro; Bolaños, Jonathan Mallillin.
Título: Growth and Immune Response of Pangasius hypophthalmus Fed Diets Containing Seaweed Extracts as Immunostimulant
Fonte: Braz. arch. biol. technol;62:e19180083, 2019. tab, graf.
Idioma: en.
Resumo: Abstract Growth and immune response of Pangasius hypophthalmus were evaluated after feeding the fish with diets containing hot-water extracts (HWE) of Sargassum oligocystum as immunostimulant at 100, 300, and 500 mg kg-1 diet. Basal diet for P. hypophthalmus served as the control. The experimental diets were administered for 12 weeks. At the end of the feeding experiment, growth and haematological profile of fish were evaluated. Result showed that final weight, weight gain, daily growth rate and feed conversion ratio were significantly increased in the fish that received 300 and 500 mg kg-1 HWE of S. oligocystum. Evaluation of the haematological profile showed that white blood cells red blood cells, hemoglobin, hematocrit and platelet of P. hypophthalmus that received the HWE of S. oligocystum were significantly higher than the control group. Overall, our results indicate that the use of S. oligocystum HWE improves growth and haematological profile in P. hypophthalmus.
Descritores: Adjuvantes Imunológicos
Sargassum
Peixes/crescimento & desenvolvimento
Imunidade
Responsável: BR1.1 - BIREME


  3 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1019809
Autor: Rodrigues, Luciano Miller Reis; Oliveira, Lilian Zerbinatti de; Silva, Mariane de Barros Ribeiro da; Accardo, Camila de Melo; Giglio, Adriana Braz Del; Pinhal, Maria Aparecida da Silva.
Título: Inflammatory biomarkers in sera of patients with intervertebral disc degeneration / Biomarcadores inflamatórios no plasma de pacientes com degeneração do disco intervertebral
Fonte: Einstein (Säo Paulo);17(4):eAO4637, 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: To evaluate intervertebral disc levels of inflammatory factor (interleukin 6) and proteinase activity (cathepsin B) in patients with a degenerative disease and serum levels of interleukin 6, serum cathepsin B activity and hyaluronic acid biomarkers. Methods: We conducted immunohistochemistry studies of intervertebral discs to analyze interleukin 6 and cathepsin B levels of patients with degenerative disease and spine fracture (Control Group) and to measure hyaluronic acid, interleukin 6 and cathepsin B activity from sera of intervertebral disc degeneration patients, fracture patients, and healthy individuals. Results: Interleukin 6 and cathepsin B seem to be related with physiopathology of intervertebral disc degeneration, since the levels of both were higher in discs of patients with intervertebral disc degeneration. Interleukin 6 and cathepsin B do not represent good biomarkers of degenerative intervertebral disc disease, since the level of such compounds is increased in the plasma of patients with fractures. Conclusion: Hyaluronic acid can be a biomarker for intervertebral disc degeneration, because hyaluronic acid levels were higher only in sera of patients with intervertebral disc degeneration.

RESUMO Objetivo: Avaliar os níveis de fatores inflamatórios nos discos intervertebrais (interleucina 6) e proteinase (catepsina B) em pacientes com doença degenerativa de disco intervertebral, além de verificar os níveis séricos de interleucina 6, ácido hialurônico e atividade sérica da catepsina B. Métodos: Foi realizado exame imuno-histoquímica dos discos intervertebrais de pacientes com doença degenerativa e fratura da coluna (Grupo Controle) e análise do plasma de pacientes com doença degenerativa de disco intervertebral. Como controle, foram utilizados plasma de pacientes com fraturas, além de indivíduos saudáveis. Resultados: Interleucina 6 e catepsina B sugerem relação com a fisiopatologia da doença degenerativa de disco intervertebral, uma vez que os níveis de ambos foram maiores nos discos de pacientes com doença degenerativa de disco intervertebral. Interleucina 6 e catepsina B não representam bons biomarcadores da doença degenerativa do disco intervertebral, já que também encontram níveis aumentados em plasma de pacientes com fratura. Conclusão: O ácido hialurônico é um possível biomarcador de doença degenerativa de disco intervertebral, porque os níveis de ácido hialurônico foram maiores apenas em plasma de pacientes com doença degenerativa de disco intervertebral.
Descritores: Catepsina B/sangue
Biomarcadores/sangue
Adjuvantes Imunológicos/sangue
Interleucina-6/sangue
Degeneração do Disco Intervertebral/diagnóstico
Ácido Hialurônico/sangue
-Imuno-Histoquímica
Estudos de Casos e Controles
Estudos Prospectivos
Análise de Variância
Sensibilidade e Especificidade
Mediadores da Inflamação/sangue
Degeneração do Disco Intervertebral/fisiopatologia
Degeneração do Disco Intervertebral/sangue
Disco Intervertebral/fisiopatologia
Limites: Humanos
Masculino
Feminino
Adulto
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  4 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1090059
Autor: Souza, Fátima Cleonice de; Mocellin, Magáli; Ongaratto, Renata; Leitão, Lidiane Alves de Azeredo; Friedrich, Frederico Orlando; Silveira, Victória d'A; Scotta, Marcelo Comerlato; Pitrez, Paulo Márcio; Pinto, Leonardo Araújo.
Título: OM-85 BV for primary prevention of recurrent airway infections: a pilot randomized, double-blind, placebo-controlled study / OM-85 BV para prevenção primária de infecções recorrentes das vias aéreas: estudo piloto, randomizado, duplo-cego, placebo-controlado
Fonte: Einstein (Säo Paulo);18:eAO5262, 2020. tab.
Idioma: en.
Resumo: ABSTRACT Objective To compare the frequency of respiratory tract infections in children treated with OM-85 BV and placebo during the 3-month therapy period, and observation for a further 3 months after treatment. Methods A randomized, double-blind, placebo-controlled trial was conducted with 54 children (6 months to 5 years old) with no past history of recurrent respiratory infections attending daycare center. Family members were instructed to administer one capsule per day for 10 consecutive days, for 3 months of OM-85 BV or placebo. Telephone interviews were conducted every 30 days. Results There was no significant difference in the number of respiratory infections between the groups. The mean number of respiratory tract infection in the OM-85 BV Group in the first 3 months was 0.92±0.87, and in the Placebo Group was 0.74±1.02, and at 6 months it was 1.62±1.47 and 1.03±1.34, respectively. Conclusion OM-85 BV was not effective in the primary prevention of respiratory tract infections. Although most authors recommend the use of this immunostimulant in children with a history of recurrent respiratory infections, more studies are needed to define its usefulness in the primary prevention of respiratory infections in healthy children exposed to few risk factors.

RESUMO Objetivo Comparar a frequência de infecções do trato respiratório em crianças tratadas com OM-85 BV e placebo durante o período de terapia de 3 meses, e observação por mais 3 meses após o tratamento. Métodos Foi realizado estudo randomizado, duplo-cego, controlado por placebo com 54 crianças (6 meses a 5 anos) sem história prévia de infecções respiratórias recorrentes, que frequentavam creches. Os membros da família foram instruídos a administrar uma cápsula por dia durante 10 dias consecutivos, durante 3 meses, de OM-85 BV ou placebo. Entrevistas telefônicas foram realizadas a cada 30 dias. Resultados Não houve diferença significativa no número de infecções respiratórias entre os grupos. O número médio de infecções do trato respiratório no Grupo OM-85 BV nos primeiros 3 meses foi de 0,92±0,87 e, no Grupo Placebo, de 0,74±1,02, e aos 6 meses foi de 1,62±1,47 e 1,03±1,34, respectivamente. Conclusão O OM-85 BV não foi eficaz na prevenção primária de infecções do trato respiratório. Embora a maioria dos autores recomende o uso deste imunoestimulante em crianças com história de infecções respiratórias recorrentes, mais estudos são necessários para definir sua utilidade na prevenção primária de infecções respiratórias em crianças saudáveis expostas a poucos fatores de risco.
Descritores: Prevenção Primária/métodos
Extratos Celulares/uso terapêutico
Adjuvantes Imunológicos/uso terapêutico
-Infecções Respiratórias/tratamento farmacológico
Poluição por Fumaça de Tabaco
Aleitamento Materno
Creches
Projetos Piloto
Método Duplo-Cego
Resultado do Tratamento
Limites: Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  5 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-964052
Autor: Méndez-López, T T; Rodríguez-Orozco, A R; Béjar Lozano, C.
Título: Efecto comparado de dosis inmunoestimulantes de fracciones ribosomales y proteoglicanos de membrana sobre la activación de subpoblaciones de células mononucleadas humanas de sangre periférica / Compared effect of immunostimulatory dose of ribosomal fractions and membrane proteoglycans on the activation of human mononuclear cell subsets from peripheral blood
Fonte: Arch. alerg. inmunol. clin;43(1):10-14, 2012.
Idioma: es.
Resumo: Antecedentes. La población mexicana presenta una alta prevalencia de infecciones recurrentes de vías respiratorias altas. Objetivos. Comparar el efecto de dosis inmunoestimulantes de ribosomas bacterianos y proteoglicanos de membrana Ribovac® sobre células mononucleadas. Material y métodos. La expresión de IL-6 de células mononucleadas en cultivo, se midió a concentraciones y tiempos variables por la técnica de ELISA, mientras que el efecto de Ribovac® en poblaciones de células mononucleadas fue analizado por citometría de flujo. Resultados. Ribovac® tiene un efecto dependiente de dosis y tiempo de exposición sobre la expresión de IL-6 por células mononucleadas; las concentraciones de IL-6 fueron máximas a las 6 horas de tratamiento con Ribovac®. La expresión de CD3+ fue mayor cuando las células mononucleadas se trataron con 125 µg/ml por 72 horas (p=0,010) respecto a aquellas que se trataron a mitad de esa concentración en igual tiempo, a diferencia de la expresión de CD19, que fue mayor en células mononucleadas tratadas con 62,5 µg/ml por 72 horas que en aquellas tratadas con 125 µg/ml por 72 horas (p=0,021). No se encontraron disminuciones estadísticamente significativas en el número de células CD16+CD56+ ni en la coexpresión de los marcadores CD45 y CD19 cuando se compararon tanto tiempos de administración como concentraciones de Ribovac®. Conclusiones. La expansión de poblaciones linfoides y la maduración de éstas a fenotipos con mayor capacidad efectora son efectos inducibles y deseables de Ribovac®, que deben tenerse en cuenta al decidir su tiempo e intervalos de administración.(AU)

Background. The Mexican population has a high prevalence of recurrent infections of upper respiratory tract. Objective. To compare the effect of immunostimulatory dose of bacterial ribosomes and membrane proteoglycan Ribovac® on mononuclear cells. Methods. The expression of interleukin 6 from mononuclear cells in culture was measured at varying concentrations and times by ELISA, while the effect of R in populations of mononuclear cells was analyzed by flow cytometry. Results. Ribovac® has an dose-dependent and exposure time effect on the expression of IL-6 by mononuclear cells, concentrations of IL-6 were maximal at 6 hours of treatment with Ribovac®. The expression of CD3+ was higher when mononuclear cells weretreated with 125 µg/ml for 72 hours (p=0,010) than those who were treated to half that concentration in the same time, unlike the expression of CD19 which was higher in mononuclear cells treated with 62,5 µg/ml for 72 hours than those that were treated with 125 µg/ml for 72 hours (p=0,021). There were no statistically significance in the decrease in the number of CD16+CD56+ cells and in the coexpression of CD45 and CD19 markers neither; when comparing both times of administration and evaluated concentrations of Ribovac®. Conclusions. The lymphoid population expansion and their maturation to better effector phenotypes effector are inducible and desirable effects of Ribovac® and these important when deciding the time and intervals of administration.(AU)
Descritores: Proteoglicanas
Ribossomos
Adjuvantes Imunológicos
-Infecções Respiratórias
Leucócitos Mononucleares
Limites: Humanos
Tipo de Publ: Estudo de Avaliação
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco


  6 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1045847
Autor: Qiu, ZL; Wang, ZJ; Huang, JK; Dou, HH; Zhen, CM; Cheng, F.
Título: The Effect of Thymosin Alpha 1 on Severe Acute Pancreatitis in Rats / Estudios sobre el efecto de la timosina alfa 1 sobre la pancreatitis aguda grave en ratas
Fonte: West Indian med. j;67(3):238-242, July-Sept. 2018. tab.
Idioma: en.
Projeto: Natural Science Foundation of Anhui Province Educational Committee; . Natural Science Foundation of Bengbu Medical College.
Resumo: ABSTRACT Objective: To observe the effect of thymosin alpha l (Tα1) on severe acute pancreatitis (SAP) in rats. Methods: Twenty-four adult male Sprague-Dawley rats were randomly divided into three groups (eight in each group): control group (Group A), SAP group (Group B) and Tα1 treatment group (Group C). Animal models of SAP were made by retrograde injection of 5% sodium taurocholate into the biliopancreatic duct. Rats in Group C were treated with Tα1 (6 mg/kg) via intraperitoneal administration prior to SAP modelling. Eight rats in each group were sacrificed at 12 hours, respectively, after modelling. The serum levels of amylase, tumour necrosis factor-α (TNF-α), interleukin-lβ (IL-lβ and interleukin-6 (IL-6) were detected in each group. The pathological scores of the tissue in the pancreas head were observed by light microscopy. Results: The levels of serum amylase of Group B were 6378 ± 538 U/L, which were significantly higher than those (4587 ± 478 U/L) of Group C (p < 0.05). The levels of serum TNF-α of Group B were 360.32 ± 28.67 pg/mL, which were higher than those (269.99 ± 26.11 pg/mL) of Group C (p < 0.05). The levels of serum IL-lβ of Group B were 435.93 ± 36.00 pg/mL, which were higher than those (312.42 ± 17.89 pg/mL) of Group C (p < 0.05). The levels of serum IL-6 of Group B were 433.90 ± 28.36 pg/mL, which were higher than those (289.98 ± 23.00 pg/mL) of Group C (p < 0.05). The pancreatic pathological scores of Group B were 13.34 ± 2.19, which were higher than those (6.39 ± 1.86) of Group C (p < 0.05). Conclusion: Thymosin alpha 1 could decrease proinflammatory cytokines and reduce pancreas injury and had a protective effect in rats with SAP. This provides a new strategy for the clinical treatment of SAP.

RESUMEN Objetivo: Observar el efecto de la timosina alfa l (Tα1) sobre la pancreatitis aguda grave (PAG) en ratas. Métodos: Veinticuatro ratas Sprague-Dawley adultas machos fueron divididas aleatoriamente en tres grupos (ocho en cada grupo): grupo de control (grupo A), grupo de PAG (grupo B) y grupo de tratamiento con Tα1 (grupo C). Los modelos animales de PAG fueron creados mediante inyección retrógrada de taurocolato de sodio al 5% en el conducto biliopancreático. Las ratas del grupo C se trataron con Tα1 (6 mg/kg) via administración intraperitoneal antes del modelado de PAG. Las ocho ratas en cada grupo fueron sacrificadas a las 12 horas, respectivamente, después del modelado. Los niveles séricos de amilasa, factor-α de necrosis tumoral (TNF-α), interleucina-β (Il-β) e interleucina-6 (IL-6) fueron detectados en cada grupo. Las puntuaciones patológicas del tejido en la cabeza del páncreas fueron observadas mediante microscopía de luz. Resultados: Los niveles de amilasa sérica del grupo B fueron 6378 ± 538 U/L, y resultaron significativamente más altos (p < 0.05) que los niveles 4587 ± 478 U/L del grupo C. Los niveles séricos de TNF-α del grupo B fueron 360.32 ± 28.67 pg/mL, y resultaron ser más altos (p < 0.05) que los 269.99 ± 26.11 pg/mL del grupo C. Los niveles séricos de Il-β del grupo B fueron 435.93 ± 36.00 pg/mL, y fueron más altos (p < 0.05) que los 312.42 ± 17.89 pg/mL) del grupo C. Los niveles de suero IL-6 del grupo B fueron 433.90 ± 28.36 pg/mL, y resultaron ser más altos (p < 0.05) que los 289.98 ± 23.00 pg/mL del grupo C. Las puntuaciones patológicas pancreáticas del grupo B fueron 13.34 ± 2.19, y resultaron ser más altas (p < 0.05) que las puntuaciones 6.39 ± 1.86 del grupo C. Conclusión: La timosina alfa pudo disminuir las citoquinas proinflamatorias y reducir la lesión del páncreas, y tuvo un efecto protector en las ratas con PAG. Esto ofrece una nueva estrategia para el tratamiento clínico de PAG.
Descritores: Pancreatite/tratamento farmacológico
Biomarcadores/sangue
Adjuvantes Imunológicos/administração & dosagem
Timalfasina/administração & dosagem
-Índice de Gravidade de Doença
Doença Aguda
Interleucinas/sangue
Fator de Necrose Tumoral alfa/sangue
Ratos Sprague-Dawley
Modelos Animais de Doenças
Amilases/sangue
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  7 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1002193
Autor: Racioppi, Marco; Gianfrancesco, Luca Di; Ragonese, Mauro; Palermo, Giuseppe; Sacco, Emilio; Bassi, Pier Francesco.
Título: Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
Fonte: Int. braz. j. urol;45(2):315-324, Mar.-Apr. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To evaluate the neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for response of high risk non muscle invasive bladder cancer (HRNMIBC) treated with BCG therapy. Materials and Methods: Between March 2010 and February 2014 in a tertiary center 100 consecutive patients with newly diagnosed HRNMIBC were retrospectively analyzed. Patients were divided according to NLR value: 46 patients with NLR value less than 3 (NLR < 3 group), and 54 patients with NLR value more than 3 (NLR ≥ 3 group). At the end of follow-up 52 patients were high grade disease free (BCG-responder group) and 48 patients underwent radical cystectomy for high grade recurrence or progression to muscle invasive disease (BCG non-responder group). The average follow-up was 60 months. Intervention: analysis and correlation of preoperative NLR value with response to BCG in terms of recurrence and progression. Results: The optimal cut-off for NLR was ≥ 3 according to the receiver operating characteristics analysis (AUC 0.760, 95% CI, 0.669-0.850). Mean NLR value was 3.65 ± 1.16 in BCG non-responder group and 2.61 ± 0.77 in BCG responder group (p = 0.01). NLR correlated with recurrence (r = 0.55, p = 0.01) and progression risk scores (r = 0.49, p = 0.01). In multivariate analysis, NLR (p = 0.02) and EORTC recurrence risk groups (p = 0.01) were associated to the primary endpoint. The log-rank test showed statistically significant difference between NLR < 3 and NLR ≥ 3 curves (p < 0.05). Conclusions: NLR value preoperatively evaluated could be a useful tool to predict BCG response of HRNMIBC. These results could lead to the development of prospective studies to assess the real prognostic value of NLR in HRNMIBC.
Descritores: Neoplasias da Bexiga Urinária/tratamento farmacológico
Vacina BCG/uso terapêutico
Linfócitos/patologia
Carcinoma de Células de Transição/tratamento farmacológico
Adjuvantes Imunológicos/uso terapêutico
Neutrófilos/patologia
-Prognóstico
Neoplasias da Bexiga Urinária/cirurgia
Neoplasias da Bexiga Urinária/patologia
Carcinoma de Células de Transição/cirurgia
Carcinoma de Células de Transição/patologia
Biomarcadores Tumorais/sangue
Cistectomia
Estudos Retrospectivos
Contagem de Linfócitos
Progressão da Doença
Gradação de Tumores
Pessoa de Meia-Idade
Recidiva Local de Neoplasia/cirurgia
Estadiamento de Neoplasias
Limites: Humanos
Masculino
Feminino
Idoso
Responsável: BR1.1 - BIREME


  8 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1223773
Autor: Villena, Rodolfo; Bastías, Magdalena.
Título: Priorización de nuevas vacunas e innovación al servicio de estrategias de vacunación / New vaccines prioritization and immunization-related innovation
Fonte: Rev. Méd. Clín. Condes;31(3/4):343-351, mayo.-ago. 2020. tab.
Idioma: es.
Resumo: La vacunación es el medio más efectivo para controlar la morbilidad y mortalidad relacionadas con enfermedades infecciosas. Para lograr esto, necesitamos vacunas inmunogénicas y seguras que faciliten y mejoren sus condiciones de transporte, almacenamiento y administración. Gracias a los avances en inmunología y bioinformática, es posible impulsar el descubrimiento de nuevas vacunas para enfrentar la tuberculosis, el virus respiratorio sincicial, el Streptococcus agalactiae, la enfermedad meningocócica invasora, entre otros. Así también, nuevas tecnologías, como la producción de vacunas utilizando plantas transgénicas y parches de microagujas, los cuales podrían facilitar la producción, disminuir los costos y efectos adversos. Sin embargo, no solo necesitamos las vacunas, sino que debemos conocer la epidemiología de las enfermedades prevenibles con vacuna para tomar decisiones fundadas, con el objetivo de planificar estrategias sanitarias, medir su impacto y evaluar la seguridad de su utilización, para alcanzar las metas de salud pública y la confianza de la población.

Vaccination is the most effective strategy to avoid morbidity and mortality related to infectious diseases. To achieve this, we need immunogenic and safe vaccines that facilitate and improve its transport, storage and administration conditions. Thanks to current advances in immunology and bioinformatics, it is possible to boost the discovery of new vaccines to deal with tuberculosis, the respiratory syncytial virus, Streptococcus agalactiae, meningococcal invasive disease, among others. In addition to new technologies such as the production of plant-based vaccines, and microneedles patches, which can facilitate its production, reducing costs and adverse effects. However, vaccines is not the only thing that we need, because we must know the epidemiology and burden of disease to take informed decisions to design optimal strategies, measuring their impact and assessing the safety of their use in order to achieve the goals health and population confidence.
Descritores: Vacinas/administração & dosagem
Controle de Doenças Transmissíveis/métodos
Vacinação/tendências
Prioridades em Saúde
-Infecções Estreptocócicas/prevenção & controle
Adjuvantes Imunológicos
Imunização/tendências
Infecções por Vírus Respiratório Sincicial/prevenção & controle
Vacinas contra Vírus Sincicial Respiratório/administração & dosagem
Vacinas contra a Tuberculose/administração & dosagem
Decisões
Infecções Meningocócicas/prevenção & controle
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  9 / 344 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1151839
Autor: Verna, Melina; Carrara, Carolina.
Título: La vacuna de subunidades recombinantes para herpes zoster demostró ser eficaz en adultos mayores / Adjuvanted herpes zoster subunit vaccine proved to be effective in older adults
Fonte: Evid. actual. práct. ambul;19(3):77-78, 2016. ilus, tab.
Idioma: es.
Descritores: Vacina contra Herpes Zoster/imunologia
Herpes Zoster/prevenção & controle
-Ensaios Clínicos Controlados Aleatórios como Assunto
Adjuvantes Imunológicos
Estudos Multicêntricos como Assunto
Vacinas de Subunidades/efeitos adversos
Vacinas de Subunidades/imunologia
Neuralgia Pós-Herpética/prevenção & controle
Vacina contra Herpes Zoster/administração & dosagem
Vacina contra Herpes Zoster/efeitos adversos
Herpes Zoster/imunologia
Limites: Humanos
Masculino
Feminino
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Comentário
Responsável: AR2.1 - Biblioteca Central


  10 / 344 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1132173
Autor: Silveira, Marcelle Moura; Conceição, Fabricio Rochedo; Mendonça, Marcelo; Moreira, Gustavo Marçal Schmidt Garcia; Cunha, Carlos Eduardo Pouey da; Rizzi, Caroline; Hartwig, Daiane Drawanz; Moreira, Angelita da Silveira; Vendrusculo, Claire Tondo; Moreira, Ângela Nunes.
Título: Biopolymer Xanthan: A New Adjuvant for DNA Vaccines
Fonte: Braz. arch. biol. technol;63:e20190090, 2020. graf.
Idioma: en.
Resumo: Abstract DNA vaccines have been evaluated as an option to prevent several diseases. In this study, the capacity of the xanthan biopolymer to improve the DNA vaccines immune response, administered intramuscularly, was evaluated. The experimental vaccines consisted of genes encoding fragments of the proteins LigA and LigB of Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni strain Fiocruz L1-130. The humoral immune response was evaluated by indirect ELISA. Cytokine expression levels were determined by RT-qPCR. Compared to the control group, the IgG antibody levels of animals immunized with pTARGET/ligAni and pTARGET/ligBrep plasmids associated with xanthan biopolymer were significantly higher than the control group. Additionally, there was a significant increase in IL-17 expression in animals vaccinated with pTARGET/ligBrep and xanthan.
Descritores: Polissacarídeos Bacterianos
DNA Recombinante/farmacologia
Adjuvantes Imunológicos/farmacologia
Xanthomonas campestris
Vacinas de DNA/farmacologia
-Biopolímeros/farmacologia
Ensaio de Imunoadsorção Enzimática
Leptospira interrogans serovar icterohaemorrhagiae
Anticorpos
Limites: Animais
Feminino
Camundongos
Responsável: BR1.1 - BIREME



página 1 de 35 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde